
    
      The first group of 30 protocol-qualified subjects will be assigned to Treatment Group 1 and
      given 1% AN2690 Solution. The second group of 30 protocol-qualified subjects will be assigned
      to Treatment Group 2 and given 5% AN2690 Solution.
    
  